|
G |
Cartpt |
CART prepropeptide |
multiple interactions |
EXP |
alpha-MSH binds to and results in increased activity of CARTPT protein |
CTD |
PMID:15659233 |
|
NCBI chr 2:32,989,215...32,991,794
Ensembl chr 2:31,255,098...31,290,713
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
ISO |
alpha-MSH results in increased phosphorylation of MAPK1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [alpha-MSH results in increased phosphorylation of MAPK1 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Phytol promotes the reaction [alpha-MSH results in increased phosphorylation of MAPK1 protein]]; Acetylcysteine affects the reaction [Phytol promotes the reaction [alpha-MSH results in increased phosphorylation of MAPK1 protein]]; Phytol promotes the reaction [alpha-MSH results in increased phosphorylation of MAPK1 protein]; Resveratrol promotes the reaction [alpha-MSH results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:29486182 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [alpha-MSH results in increased phosphorylation of MAPK3 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Phytol promotes the reaction [alpha-MSH results in increased phosphorylation of MAPK3 protein]]; Acetylcysteine affects the reaction [Phytol promotes the reaction [alpha-MSH results in increased phosphorylation of MAPK3 protein]]; Phytol promotes the reaction [alpha-MSH results in increased phosphorylation of MAPK3 protein]; Resveratrol promotes the reaction [alpha-MSH results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:29486182 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mitf |
melanocyte inducing transcription factor |
multiple interactions increases expression |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Phytol inhibits the reaction [alpha-MSH results in increased expression of MITF protein]] which results in decreased ubiquitination of MITF protein]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Phytol inhibits the reaction [alpha-MSH results in increased expression of MITF protein]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one promotes the reaction [alpha-MSH results in increased expression of MITF protein]; [Phytol inhibits the reaction [alpha-MSH results in increased expression of MITF protein]] which results in decreased ubiquitination of MITF protein; Acetylcysteine inhibits the reaction [Phytol inhibits the reaction [alpha-MSH results in increased expression of MITF protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Phytol inhibits the reaction [alpha-MSH results in increased expression of MITF protein]] which results in decreased ubiquitination of MITF protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Phytol inhibits the reaction [alpha-MSH results in increased expression of MITF protein]]; Phytol inhibits the reaction [alpha-MSH results in increased expression of MITF protein]; Resveratrol inhibits the reaction [alpha-MSH results in increased expression of MITF protein] |
CTD |
PMID:29486182 |
|
NCBI chr 4:131,965,676...132,177,790
Ensembl chr 4:130,409,217...130,621,145
|
|
G |
Retn |
resistin |
increases expression |
ISO |
alpha-MSH analog results in increased expression of RETN mRNA |
CTD |
PMID:15522996 |
|
NCBI chr12:6,508,653...6,511,115
Ensembl chr12:1,710,881...1,712,620
|
|
G |
Tyr |
tyrosinase |
multiple interactions increases activity increases expression |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Phytol inhibits the reaction [alpha-MSH results in increased expression of TYR protein]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one promotes the reaction [alpha-MSH results in increased expression of TYR protein]; alisol B inhibits the reaction [alpha-MSH results in increased activity of TYR protein]; glabridin inhibits the reaction [alpha-MSH results in increased activity of TYR protein]; Phytol inhibits the reaction [alpha-MSH results in increased expression of TYR protein]; Resveratrol inhibits the reaction [alpha-MSH results in increased expression of TYR protein] |
CTD |
PMID:28051915 PMID:29486182 |
|
NCBI chr 1:150,527,687...150,622,857
Ensembl chr 1:141,115,036...141,210,207
|
|
G |
Tyrp1 |
tyrosinase-related protein 1 |
increases expression multiple interactions |
ISO |
alpha-MSH results in increased expression of TYRP1 protein Phytol inhibits the reaction [alpha-MSH results in increased expression of TYRP1 protein] |
CTD |
PMID:29486182 |
|
NCBI chr 5:100,327,111...100,345,657
Ensembl chr 5:95,280,982...95,299,516
|
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
affects abundance |
ISO |
[ACE2 protein affects the abundance of Angiotensin I] which affects the abundance of angiotensin I (1-7); [ACE2 protein affects the abundance of Angiotensin I] which affects the abundance of Angiotensin II; ACE2 protein affects the abundance of Angiotensin I |
CTD |
PMID:27649628 |
|
NCBI chr X:33,925,458...33,972,851
Ensembl chr X:30,293,589...30,340,977
|
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
affects abundance |
ISO |
[ACE2 protein affects the abundance of Angiotensin I] which affects the abundance of Angiotensin II; ACE2 protein affects the abundance of Angiotensin II |
CTD |
PMID:27649628 |
|
NCBI chr X:33,925,458...33,972,851
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
ISO |
[[Lisinopril co-treated with chymostatin] affects the metabolism of AGT protein] which results in decreased abundance of Angiotensin II; [Lisinopril affects the metabolism of AGT protein] which results in decreased abundance of Angiotensin II |
CTD |
PMID:27649628 |
|
NCBI chr19:69,426,540...69,447,017
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Agtr2 |
angiotensin II receptor, type 2 |
increases expression |
EXP |
Angiotensin II results in increased expression of AGTR2 mRNA; Angiotensin II results in increased expression of AGTR2 protein |
CTD |
PMID:12969123 |
|
NCBI chr X:116,914,320...116,918,504
Ensembl chr X:112,120,228...112,124,057
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO |
naoxintong inhibits the reaction [Angiotensin II results in increased expression of BAX mRNA] |
CTD |
PMID:38230784 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
increases expression |
ISO |
angiotensin II increases expression of mRNA in mouse heart |
RGD |
PMID:26873969 |
RGD:11526363 |
NCBI chr 3:141,264,648...141,275,416
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
increases expression |
ISO |
angiotensin II increases expression of mRNA in mouse heart |
RGD |
PMID:26873969 |
RGD:11526363 |
NCBI chr15:22,098,191...22,113,145
Ensembl chr15:19,618,542...19,623,306
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions increases expression |
ISO |
naoxintong inhibits the reaction [Angiotensin II results in increased expression of CCL2 mRNA] |
CTD |
PMID:38230784 |
|
NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions increases expression |
ISO |
NFE2L2 protein affects the reaction [Angiotensin II results in increased expression of COL1A1 mRNA] |
CTD |
PMID:33746155 |
|
NCBI chr10:80,380,458...80,397,461
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
increases expression |
ISO |
Angiotensin II results in increased expression of COL3A1 mRNA |
CTD |
PMID:33746155 |
|
NCBI chr 9:54,866,646...54,902,578
Ensembl chr 9:47,374,593...47,410,547
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions decreases expression |
EXP |
celastrol methyl ester inhibits the reaction [Angiotensin II results in decreased expression of CPT1A mRNA]; PPARA protein promotes the reaction [celastrol methyl ester inhibits the reaction [Angiotensin II results in decreased expression of CPT1A mRNA]] |
CTD |
PMID:37269933 |
|
NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Ednrb |
endothelin receptor type B |
increases expression |
EXP |
Angiotensin II results in increased expression of EDNRB protein |
CTD |
PMID:15007106 |
|
NCBI chr15:87,055,490...87,086,765
Ensembl chr15:80,643,043...80,672,115
|
|
G |
Esrra |
estrogen related receptor, alpha |
decreases expression multiple interactions |
EXP |
Angiotensin II results in decreased expression of ESRRA protein celastrol methyl ester inhibits the reaction [Angiotensin II results in decreased expression of ESRRA protein]; PPARA protein promotes the reaction [celastrol methyl ester inhibits the reaction [Angiotensin II results in decreased expression of ESRRA protein]] |
CTD |
PMID:37269933 |
|
NCBI chr 1:213,533,309...213,543,432
Ensembl chr 1:204,104,101...204,114,268
|
|
G |
Fis1 |
fission, mitochondrial 1 |
multiple interactions increases expression |
ISO |
naoxintong inhibits the reaction [Angiotensin II results in increased expression of FIS1 protein] |
CTD |
PMID:38230784 |
|
NCBI chr12:25,345,239...25,360,135
Ensembl chr12:19,708,558...19,723,377
|
|
G |
Id1 |
inhibitor of DNA binding 1 |
increases expression |
ISO |
angiotensin II increases expression of mRNA in mouse heart |
RGD |
PMID:26873969 |
RGD:11526363 |
NCBI chr 3:161,671,525...161,672,691
Ensembl chr 3:141,211,267...141,212,419
|
|
G |
Il1b |
interleukin 1 beta |
increases expression multiple interactions |
ISO |
Angiotensin II results in increased expression of IL1B mRNA naoxintong inhibits the reaction [Angiotensin II results in increased expression of IL1B mRNA] |
CTD |
PMID:38230784 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression |
ISO |
naoxintong inhibits the reaction [Angiotensin II results in increased expression of IL6 protein] |
CTD |
PMID:38230784 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Jak2 |
Janus kinase 2 |
increases phosphorylation |
ISO |
Angiotensin II increases phosphorylation of JAK2 protein in liver |
RGD |
PMID:22613986 |
RGD:127285667 |
NCBI chr 1:236,408,905...236,468,769
Ensembl chr 1:226,995,334...227,054,189
|
|
G |
Klf4 |
KLF transcription factor 4 |
increases expression |
ISO |
angiotensin II increases expression of KLF4 mRNA and protein in vascular smooth muscle cells |
RGD |
PMID:29127880 |
RGD:155230825 |
NCBI chr 5:75,074,107...75,079,182
Ensembl chr 5:70,278,972...70,283,602
|
|
G |
Map3k7 |
mitogen activated protein kinase kinase kinase 7 |
increases expression |
ISO |
Angiotensin II increases expression of MAP3K7 mRNA in cardiomyocytes |
RGD |
PMID:30854566 |
RGD:155791647 |
NCBI chr 5:51,149,524...51,212,012
Ensembl chr 5:46,357,931...46,415,597
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
decreases expression multiple interactions |
ISO |
Angiotensin II results in decreased expression of MCL1 protein naoxintong inhibits the reaction [Angiotensin II results in decreased expression of MCL1 protein] |
CTD |
PMID:38230784 |
|
NCBI chr 2:185,884,840...185,912,532
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Mir143 |
microRNA 143 |
decreases expression |
ISO |
Angiotensin II decreases expression of miRNA143 RNA in vascular smooth muscle cells |
RGD |
PMID:28167124 |
RGD:155260287 |
NCBI chr18:57,371,349...57,371,453
Ensembl chr18:55,101,006...55,101,110
|
|
G |
Mir145 |
microRNA 145 |
decreases expression |
ISO |
angiotensin II decreases expression of MIR145a RNA in vascular smooth muscle cell Angiotensin II decreases expression of miRNA145 RNA in vascular smooth muscle cells |
RGD |
PMID:29127880 PMID:28167124 |
RGD:155230825, RGD:155260287 |
NCBI chr18:57,369,983...57,370,070
Ensembl chr18:55,099,640...55,099,727
|
|
G |
Myh6 |
myosin heavy chain 6 |
multiple interactions decreases expression |
EXP |
celastrol methyl ester inhibits the reaction [Angiotensin II results in decreased expression of MYH6 mRNA alternative form] |
CTD |
PMID:37269933 |
|
NCBI chr15:32,388,102...32,413,663
Ensembl chr15:28,417,616...28,441,720
|
|
G |
Myocd |
myocardin |
decreases expression |
ISO |
angiotensin II decreases expression of MYOCD mRNA and protein in vascular smooth muscle cell |
RGD |
PMID:29127880 |
RGD:155230825 |
NCBI chr10:50,332,356...50,426,819
Ensembl chr10:49,836,641...49,927,627
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
NFE2L2 protein affects the reaction [Angiotensin II results in increased expression of COL1A1 mRNA]; NFE2L2 protein affects the reaction [Angiotensin II results in increased expression of NOX4 protein] |
CTD |
PMID:33746155 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nox4 |
NADPH oxidase 4 |
multiple interactions increases expression |
ISO |
NFE2L2 protein affects the reaction [Angiotensin II results in increased expression of NOX4 protein] Angiotensin II results in increased expression of NOX4 mRNA naoxintong inhibits the reaction [Angiotensin II results in increased expression of NOX4 mRNA] |
CTD |
PMID:33746155 PMID:38230784 |
|
NCBI chr 1:150,313,736...150,491,480
Ensembl chr 1:140,901,097...141,077,406
|
|
G |
Nphs1 |
NPHS1 adhesion molecule, nephrin |
multiple interactions |
ISO |
angiotensin II inhibits reaction [fluvastatin increases expression of Nphs1 protein in kidney] |
RGD |
PMID:19188342 |
RGD:38596324 |
NCBI chr 1:94,848,261...94,876,522
Ensembl chr 1:85,720,812...85,749,078
|
|
G |
Nppa |
natriuretic peptide A |
increases expression multiple interactions |
ISO EXP |
angiotensin II increases expression of mRNA in mouse heart Angiotensin II results in increased expression of NPPA mRNA celastrol methyl ester inhibits the reaction [Angiotensin II results in increased expression of NPPA mRNA] |
CTD RGD |
PMID:37269933 PMID:26873969 |
RGD:11526363 |
NCBI chr 5:163,712,184...163,713,493
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nppb |
natriuretic peptide B |
increases expression multiple interactions |
ISO EXP |
angiotensin II increases expression of mRNA in mouse heart Angiotensin II results in increased expression of NPPB mRNA celastrol methyl ester inhibits the reaction [Angiotensin II results in increased expression of NPPB mRNA] |
CTD RGD |
PMID:37269933 PMID:26873969 |
RGD:11526363 |
NCBI chr 5:163,699,955...163,701,314
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
increases expression |
ISO |
Angiotensin II decreases expression of NR1H3 mRNA and protein in macrophages |
RGD |
PMID:25225013 |
RGD:401827926 |
NCBI chr 3:97,614,616...97,632,053
Ensembl chr 3:77,158,808...77,168,722
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
affects response to substance |
ISO |
NR1I2 protein affects the susceptibility to Angiotensin II |
CTD |
PMID:33746155 |
|
NCBI chr11:75,965,717...76,006,733
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Pdha1 |
pyruvate dehydrogenase E1 subunit alpha 1 |
multiple interactions decreases expression |
EXP |
celastrol methyl ester inhibits the reaction [Angiotensin II results in decreased expression of PDHA1 mRNA]; PPARA protein promotes the reaction [celastrol methyl ester inhibits the reaction [Angiotensin II results in decreased expression of PDHA1 mRNA]] |
CTD |
PMID:37269933 |
|
NCBI chr X:38,509,158...38,522,986
Ensembl chr X:34,700,409...34,714,311
|
|
G |
Pfkm |
phosphofructokinase, muscle |
increases expression multiple interactions |
EXP |
Angiotensin II results in increased expression of PFKM mRNA celastrol methyl ester inhibits the reaction [Angiotensin II results in increased expression of PFKM mRNA]; PPARA protein promotes the reaction [celastrol methyl ester inhibits the reaction [Angiotensin II results in increased expression of PFKM mRNA]] |
CTD |
PMID:37269933 |
|
NCBI chr 7:131,100,684...131,138,250
Ensembl chr 7:129,221,653...129,259,192
|
|
G |
Postn |
periostin |
increases expression |
ISO |
Angiotensin II results in increased expression of POSTN mRNA; Angiotensin II results in increased expression of POSTN protein |
CTD |
PMID:33746155 |
|
NCBI chr 2:140,677,774...140,709,304
Ensembl chr 2:138,527,696...138,559,099
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
EXP |
PPARA protein promotes the reaction [celastrol methyl ester inhibits the reaction [Angiotensin II results in decreased expression of CPT1A mRNA]]; PPARA protein promotes the reaction [celastrol methyl ester inhibits the reaction [Angiotensin II results in decreased expression of ESRRA protein]]; PPARA protein promotes the reaction [celastrol methyl ester inhibits the reaction [Angiotensin II results in decreased expression of PDHA1 mRNA]]; PPARA protein promotes the reaction [celastrol methyl ester inhibits the reaction [Angiotensin II results in decreased expression of TFAM protein]]; PPARA protein promotes the reaction [celastrol methyl ester inhibits the reaction [Angiotensin II results in increased expression of PFKM mRNA]] |
CTD |
PMID:37269933 |
|
NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions decreases expression |
EXP |
celastrol methyl ester inhibits the reaction [Angiotensin II results in decreased expression of PPARGC1A protein] |
CTD |
PMID:37269933 |
|
NCBI chr14:63,073,505...63,729,215
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ppargc1b |
PPARG coactivator 1 beta |
decreases expression multiple interactions |
EXP |
Angiotensin II results in decreased expression of PPARGC1B protein celastrol methyl ester inhibits the reaction [Angiotensin II results in decreased expression of PPARGC1B protein] |
CTD |
PMID:37269933 |
|
NCBI chr18:57,029,264...57,131,466
Ensembl chr18:54,758,902...54,861,194
|
|
G |
Prkd1 |
protein kinase D1 |
affects localization |
EXP |
Angiotensin II affects localization of Prkd1 protein in cardiomyocytes |
RGD |
PMID:15652511 |
RGD:288084581 |
NCBI chr 6:73,460,640...73,774,433
Ensembl chr 6:67,725,905...68,039,042
|
|
G |
Ptpn1 |
protein tyrosine phosphatase, non-receptor type 1 |
increases expression |
EXP |
Angiotensin II increases expression of Ptpn1 protein in cardiac microvascular endothelial cells |
RGD |
PMID:31502193 |
RGD:401976382 |
NCBI chr 3:177,056,588...177,106,424
Ensembl chr 3:156,638,769...156,687,504
|
|
G |
Rbfox2 |
RNA binding fox-1 homolog 2 |
decreases expression |
EXP |
Angiotensin II decreases expression of Rbfox2 mRNA and protein in vascular smooth muscle cells |
RGD |
PMID:28993448 |
RGD:329848961 |
NCBI chr 7:110,691,230...110,934,901
Ensembl chr 7:108,810,628...109,054,691
|
|
G |
Sox17 |
SRY-box transcription factor 17 |
increases expression decreases expression |
ISO |
Angiotensin II increases expression of SOX17 mRNA and protein in retinal microvascular endothelial cells Angiotensin II decreases expression of SOX17 protein in retinal endothelial cells |
RGD |
PMID:36200131 PMID:32078435 |
RGD:329853320, RGD:329853329 |
NCBI chr 5:19,814,345...19,819,859
Ensembl chr 5:15,016,731...15,022,228
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
increases expression |
ISO |
Angiotensin II increases expression of Spp1 protein in vascular smooth muscle cells |
RGD |
PMID:28167124 |
RGD:155260287 |
NCBI chr14:5,613,569...5,620,695
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Tfam |
transcription factor A, mitochondrial |
decreases expression multiple interactions |
EXP |
Angiotensin II results in decreased expression of TFAM protein celastrol methyl ester inhibits the reaction [Angiotensin II results in decreased expression of TFAM protein]; PPARA protein promotes the reaction [celastrol methyl ester inhibits the reaction [Angiotensin II results in decreased expression of TFAM protein]] |
CTD |
PMID:37269933 |
|
NCBI chr20:17,355,373...17,367,422
Ensembl chr20:17,356,197...17,368,292
|
|
G |
Tnf |
tumor necrosis factor |
increases expression multiple interactions |
ISO |
Angiotensin II results in increased expression of TNF mRNA naoxintong inhibits the reaction [Angiotensin II results in increased expression of TNF mRNA] |
CTD |
PMID:38230784 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Traf6 |
TNF receptor associated factor 6 |
increases expression |
EXP |
Angiotensin II increases expression of Traf6 protein in rat neonatal cardiomyocytes |
RGD |
PMID:27249171 |
RGD:155646134 |
NCBI chr 3:108,418,537...108,443,330
Ensembl chr 3:87,963,514...87,983,507
|
|
G |
Zeb2 |
zinc finger E-box binding homeobox 2 |
decreases expression |
EXP |
Angiotensin II decreases expression of Zeb2 mRNA and protein in rat renal artery endothelial cells |
RGD |
PMID:31881206 |
RGD:155882533 |
NCBI chr 3:49,624,028...49,754,323
Ensembl chr 3:29,218,301...29,345,157
|
|
|
G |
Avpr1a |
arginine vasopressin receptor 1A |
multiple interactions increases activity |
ISO |
vasopressin, 1-(1-mercaptocyclohexaneacetic acid)-2-(O- methyl-L-tyrosine)-8-L-arginine- inhibits the reaction [Arginine Vasopressin results in increased activity of AVPR1A protein] |
CTD |
PMID:31323226 |
|
NCBI chr 7:59,999,743...60,003,667
Ensembl chr 7:58,114,284...58,122,215
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
increases expression multiple interactions |
EXP |
Arginine Vasopressin results in increased expression of HSPB1 mRNA; Arginine Vasopressin results in increased expression of HSPB1 protein Pentobarbital inhibits the reaction [Arginine Vasopressin results in increased expression of HSPB1 mRNA]; Pentobarbital inhibits the reaction [Arginine Vasopressin results in increased expression of HSPB1 protein] |
CTD |
PMID:10839933 |
|
NCBI chr12:26,430,640...26,432,301
Ensembl chr12:20,794,028...20,795,743
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases activity multiple interactions |
EXP |
Arginine Vasopressin results in increased activity of MAPK1 protein 4'-(4,4-difluoro-5-(2-oxo-2-(4-piperidinopiperidino)ethylidene)-2,3,4,5-tetrahydro-1H-1-benzoazepine-1-carbonyl)-2-methyl-3-furanilide inhibits the reaction [Arginine Vasopressin results in increased activity of MAPK1 protein] |
CTD |
PMID:16966841 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Myl9 |
myosin light chain 9 |
increases phosphorylation |
EXP |
Arginine Vasopressin results in increased phosphorylation of MYL9 protein |
CTD |
PMID:15347643 |
|
NCBI chr 3:165,742,020...165,748,409
Ensembl chr 3:145,281,937...145,288,333
|
|
G |
Nppa |
natriuretic peptide A |
decreases response to substance |
ISO |
NPPA protein results in decreased susceptibility to Arginine Vasopressin |
CTD |
PMID:8188982 |
|
NCBI chr 5:163,712,184...163,713,493
Ensembl chr 5:158,429,042...158,430,351
|
|
|
G |
Hcrt |
hypocretin neuropeptide precursor |
decreases expression |
EXP |
salmon calcitonin results in decreased expression of HCRT mRNA |
CTD |
PMID:12686383 |
|
NCBI chr10:86,190,289...86,191,524
Ensembl chr10:85,689,465...85,691,210
|
|
G |
Pmch |
pro-melanin-concentrating hormone |
decreases expression |
EXP |
salmon calcitonin results in decreased expression of PMCH mRNA |
CTD |
PMID:12686383 |
|
NCBI chr 7:24,399,404...24,400,720
Ensembl chr 7:22,511,934...22,513,250
|
|
|
G |
Ada |
adenosine deaminase |
increases activity |
ISO |
Adrenocorticotropic Hormone results in increased activity of ADA protein |
CTD |
PMID:8868375 |
|
NCBI chr 3:172,818,174...172,842,283
Ensembl chr 3:152,398,747...152,447,088
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
increases abundance |
EXP |
CALCA protein results in increased abundance of Adrenocorticotropic Hormone |
CTD |
PMID:12639925 |
|
NCBI chr 1:178,312,636...178,317,588
Ensembl chr 1:168,878,214...168,883,105
|
|
G |
Cnp |
2',3'-cyclic nucleotide 3' phosphodiesterase |
decreases activity |
EXP |
Adrenocorticotropic Hormone results in decreased activity of CNP protein |
CTD |
PMID:3030154 |
|
NCBI chr10:86,011,504...86,018,063
Ensembl chr10:85,511,160...85,517,720
|
|
G |
Crh |
corticotropin releasing hormone |
multiple interactions increases secretion |
EXP |
Astemizole inhibits the reaction [Corticosterone inhibits the reaction [CRH protein results in increased secretion of Adrenocorticotropic Hormone]]; Corticosterone inhibits the reaction [CRH protein results in increased secretion of Adrenocorticotropic Hormone]; E 4031 inhibits the reaction [Corticosterone inhibits the reaction [CRH protein results in increased secretion of Adrenocorticotropic Hormone]]; Tetraethylammonium promotes the reaction [CRH protein results in increased secretion of Adrenocorticotropic Hormone] |
CTD |
PMID:18835572 |
|
NCBI chr 2:104,059,184...104,061,048
Ensembl chr 2:102,143,055...102,144,919
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
affects abundance |
ISO |
CYP17A1 protein affects the abundance of Adrenocorticotropic Hormone |
CTD |
PMID:18645707 |
|
NCBI chr 1:255,476,861...255,484,547
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Gh1 |
growth hormone 1 |
multiple interactions |
ISO |
Adrenocorticotropic Hormone inhibits the reaction [INS protein results in increased secretion of GH1 protein] |
CTD |
PMID:3008584 |
|
NCBI chr10:91,727,883...91,729,860
Ensembl chr10:91,228,103...91,230,078
|
|
G |
Htr2a |
5-hydroxytryptamine receptor 2A |
multiple interactions affects expression |
EXP |
Bupropion inhibits the reaction [Adrenocorticotropic Hormone affects the expression of HTR2A mRNA] |
CTD |
PMID:18239281 |
|
NCBI chr15:56,360,647...56,428,703
Ensembl chr15:49,950,804...50,020,928
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
Adrenocorticotropic Hormone inhibits the reaction [INS protein results in increased secretion of GH1 protein] |
CTD |
PMID:3008584 |
|
NCBI chr 1:207,272,738...207,421,998
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
affects abundance |
ISO |
NR3C1 gene polymorphism affects the abundance of Adrenocorticotropic Hormone |
CTD |
PMID:17716631 |
|
NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,271,681...31,393,375
|
|
G |
Ppp1r1b |
protein phosphatase 1, regulatory (inhibitor) subunit 1B |
multiple interactions |
ISO |
Cocaine promotes the reaction [PPP1R1B protein results in increased abundance of Adrenocorticotropic Hormone] |
CTD |
PMID:10516482 |
|
NCBI chr10:83,843,948...83,853,063
Ensembl chr10:83,347,731...83,356,775
|
|
G |
Ucn2 |
urocortin 2 |
increases abundance |
ISO |
UCN2 protein results in increased abundance of Adrenocorticotropic Hormone |
CTD |
PMID:16330704 |
|
NCBI chr 8:118,516,111...118,517,660
Ensembl chr 8:109,638,285...109,639,172
|
|
|
G |
Crhr1 |
corticotropin releasing hormone receptor 1 |
increases expression decreases activity multiple interactions |
EXP |
Corticotropin-Releasing Hormone results in increased expression of CRHR1 mRNA Corticotropin-Releasing Hormone results in decreased activity of CRHR1 protein Pentobarbital inhibits the reaction [Corticotropin-Releasing Hormone results in decreased activity of CRHR1 protein]; Pentobarbital inhibits the reaction [Corticotropin-Releasing Hormone results in increased expression of CRHR1 mRNA] |
CTD |
PMID:12093084 |
|
NCBI chr10:89,540,192...89,583,466
Ensembl chr10:89,040,203...89,083,481
|
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
multiple interactions |
ISO |
[gastrin 17 co-treated with CCKBR protein] results in decreased expression of BIRC2 |
CTD |
PMID:17704804 |
|
NCBI chr 8:13,253,697...13,273,672
Ensembl chr 8:4,968,842...4,988,732
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
multiple interactions |
ISO |
[gastrin 17 co-treated with CCKBR protein] results in decreased expression of BIRC3 |
CTD |
PMID:17704804 |
|
NCBI chr 8:13,285,702...13,313,329
Ensembl chr 8:5,000,845...5,015,802
|
|
G |
Cckbr |
cholecystokinin B receptor |
multiple interactions |
ISO |
[gastrin 17 co-treated with CCKBR protein] results in decreased expression of BIRC2; [gastrin 17 co-treated with CCKBR protein] results in decreased expression of BIRC3; [gastrin 17 co-treated with CCKBR protein] results in increased expression of IER3 mRNA |
CTD |
PMID:17704804 |
|
NCBI chr 1:169,183,578...169,193,583
Ensembl chr 1:159,771,733...159,814,881
|
|
G |
Ier3 |
immediate early response 3 |
multiple interactions |
ISO |
[gastrin 17 co-treated with CCKBR protein] results in increased expression of IER3 mRNA |
CTD |
PMID:17704804 |
|
NCBI chr20:2,933,173...2,934,377
Ensembl chr20:2,928,378...2,929,583
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
decreases activity |
ISO |
gastrin 17 results in decreased activity of NFKB1 protein |
CTD |
PMID:15623601 |
|
NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
decreases activity |
ISO |
gastrin 17 results in decreased activity of RELA protein |
CTD |
PMID:15623601 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Sele |
selectin E |
decreases expression |
ISO |
gastrin 17 results in decreased expression of SELE protein |
CTD |
PMID:15623601 |
|
NCBI chr13:78,935,997...78,945,905
Ensembl chr13:76,403,304...76,412,741
|
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions |
EXP |
Ghrelin inhibits the reaction [[Fructose co-treated with Streptozocin] results in decreased expression of CNR1 mRNA] |
CTD |
PMID:31468622 |
|
NCBI chr 5:53,204,867...53,230,396
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Glp1r |
glucagon-like peptide 1 receptor |
multiple interactions |
EXP |
Ghrelin inhibits the reaction [[Fructose co-treated with Streptozocin] results in decreased expression of GLP1R mRNA] |
CTD |
PMID:31468622 |
|
NCBI chr20:8,973,393...9,011,622
Ensembl chr20:8,972,004...9,010,241
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
ghrelin inhibits the reaction [High fat diet increases expression of IL1b mRNA in heart] |
RGD |
PMID:32084395 |
RGD:242905211 |
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
ghrelin inhibits the reaction [High fat diet increases expression of Il6 mRNA in heart] |
RGD |
PMID:32084395 |
RGD:242905211 |
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mir33 |
microRNA 33 |
multiple interactions |
EXP |
Ghrelin inhibits the reaction [[Fructose co-treated with Streptozocin] results in increased expression of MIR33A mRNA] |
CTD |
PMID:31468622 |
|
NCBI chr 7:115,593,952...115,594,020
Ensembl chr 7:113,713,855...113,713,923
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
ghrelin inhibits the reaction [High fat diet increases expression of Tgfb1 mRNA in heart] |
RGD |
PMID:32084395 |
RGD:242905211 |
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
ghrelin inhibits the reaction [high fat diet increases expression of TNF mRNA in heart] |
RGD |
PMID:32084395 |
RGD:242905211 |
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
Glucagon analog inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of ACTA2 mRNA]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased expression of ACTA2 mRNA] |
CTD |
PMID:29988851 |
|
NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
Glucagon analog inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of and results in decreased secretion of ADIPOQ protein]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in decreased expression of and results in decreased secretion of ADIPOQ protein] |
CTD |
PMID:29988851 |
|
NCBI chr11:91,226,524...91,240,244
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
Glucagon analog inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased activity of CAT protein]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in decreased activity of CAT protein] |
CTD |
PMID:29988851 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
Glucagon analog inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of CCL2 mRNA]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased expression of CCL2 mRNA] |
CTD |
PMID:29988851 |
|
NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO |
Glucagon analog inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of COL1A1 mRNA]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased expression of COL1A1 mRNA] |
CTD |
PMID:29988851 |
|
NCBI chr10:80,380,458...80,397,461
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
ISO |
Glucagon analog inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of CPT1A mRNA]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in decreased expression of CPT1A mRNA] |
CTD |
PMID:29988851 |
|
NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
EXP |
[Glucagon co-treated with Cyclic AMP] results in increased phosphorylation of CREB1 protein |
CTD |
PMID:22676303 |
|
NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
Glucagon analog inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of FASN mRNA]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased expression of FASN mRNA] |
CTD |
PMID:29988851 |
|
NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fgf21 |
fibroblast growth factor 21 |
multiple interactions |
ISO |
Glucagon analog promotes the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of and results in increased secretion of FGF21 protein]; Glucagon analog promotes the reaction [LEPR gene mutant form results in increased expression of and results in increased secretion of FGF21 protein] |
CTD |
PMID:29988851 |
|
NCBI chr 1:105,219,825...105,221,376
Ensembl chr 1:96,083,441...96,090,454
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
EXP |
[Glucagon co-treated with Cyclic AMP] results in increased expression of G6PC1 mRNA; Fatty Acids analog inhibits the reaction [[Glucagon co-treated with Cyclic AMP] results in increased expression of G6PC1 mRNA] |
CTD |
PMID:22676303 |
|
NCBI chr10:86,807,659...86,819,023
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Gcgr |
glucagon receptor |
multiple interactions |
ISO |
Glucagon analog binds to and results in increased activity of GCGR protein |
CTD |
PMID:29988851 |
|
NCBI chr10:106,306,803...106,314,970
Ensembl chr10:105,808,473...105,816,640
|
|
G |
Glp1r |
glucagon-like peptide 1 receptor |
multiple interactions |
ISO |
Glucagon analog binds to and results in increased activity of GLP1R protein |
CTD |
PMID:29988851 |
|
NCBI chr20:8,973,393...9,011,622
Ensembl chr20:8,972,004...9,010,241
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
Glucagon analog inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of and results in increased secretion of IL6 protein]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased expression of and results in increased secretion of IL6 protein] |
CTD |
PMID:29988851 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
ISO |
Glucagon analog inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of and results in increased secretion of INS1 protein]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased expression of and results in increased secretion of INS1 protein] |
CTD |
PMID:29988851 |
|
NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
Glucagon analog inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of and results in increased secretion of LEP protein]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased expression of and results in increased secretion of LEP protein] |
CTD |
PMID:29988851 |
|
NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lepr |
leptin receptor |
multiple interactions |
ISO |
Glucagon analog inhibits the reaction [[LEPR gene mutant form results in increased oxidation of Lipids] which results in increased abundance of Thiobarbituric Acid Reactive Substances]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in decreased activity of CAT protein]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in decreased expression of and results in decreased secretion of ADIPOQ protein]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in decreased expression of CPT1A mRNA]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in decreased expression of PPARA mRNA]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in decreased oxidation of and results in decreased metabolism of Fatty Acids]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased abundance of Cholesterol]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased abundance of Creatinine]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased abundance of Triglycerides]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased abundance of Urea]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased expression of ACTA2 mRNA]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased expression of and results in increased secretion of IL6 protein]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased expression of and results in increased secretion of INS1 protein]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased expression of and results in increased secretion of LEP protein]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased expression of and results in increased secretion of TNF protein]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased expression of CCL2 mRNA]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased expression of COL1A1 mRNA]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased expression of FASN mRNA]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased expression of MMP9 mRNA]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased expression of SCD1 mRNA]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased expression of SREBF1 mRNA]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased expression of TGFB1 mRNA]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased expression of TNF mRNA]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased oxidation of Lipids]; Glucagon analog promotes the reaction [LEPR gene mutant form results in increased expression of and results in increased secretion of FGF21 protein] |
CTD |
PMID:29988851 |
|
NCBI chr 5:121,409,735...121,593,201
Ensembl chr 5:116,289,823...116,475,908
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
Glucagon analog inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of MMP9 mRNA]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased expression of MMP9 mRNA] |
CTD |
PMID:29988851 |
|
NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions |
EXP |
[Glucagon co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA; Fatty Acids analog inhibits the reaction [[Glucagon co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA] |
CTD |
PMID:22676303 |
|
NCBI chr 3:182,348,572...182,354,521
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
Glucagon analog inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of PPARA mRNA]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in decreased expression of PPARA mRNA] |
CTD |
PMID:29988851 |
|
NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
EXP |
[Glucagon co-treated with Cyclic AMP] results in increased expression of PPARGC1A mRNA; Fatty Acids analog inhibits the reaction [[Glucagon co-treated with Cyclic AMP] results in increased expression of PPARGC1A mRNA]; Fatty Acids analog inhibits the reaction [[Glucagon co-treated with Cyclic AMP] results in increased phosphorylation of PPARGC1A protein] |
CTD |
PMID:22676303 |
|
NCBI chr14:63,073,505...63,729,215
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Scd |
stearoyl-CoA desaturase |
multiple interactions |
ISO |
Glucagon analog inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of SCD1 mRNA]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased expression of SCD1 mRNA] |
CTD |
PMID:29988851 |
|
NCBI chr 1:253,218,968...253,232,101
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
ISO |
Glucagon analog inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of SREBF1 mRNA]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased expression of SREBF1 mRNA] |
CTD |
PMID:29988851 |
|
NCBI chr10:45,507,152...45,529,164
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
Glucagon analog inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of TGFB1 mRNA]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased expression of TGFB1 mRNA] |
CTD |
PMID:29988851 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
Glucagon analog inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of and results in increased secretion of TNF protein]; Glucagon analog inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of TNF mRNA]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased expression of and results in increased secretion of TNF protein]; Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased expression of TNF mRNA] |
CTD |
PMID:29988851 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Gonadotropin-Releasing Hormone results in decreased expression of ESR1 protein]; Gonadotropin-Releasing Hormone results in increased ubiquitination of and results in increased degradation of and results in decreased expression of ESR1 protein |
CTD |
PMID:16055746 |
|
NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Ube2d2 |
ubiquitin-conjugating enzyme E2D 2 |
increases expression |
ISO |
Gonadotropin-Releasing Hormone results in increased expression of UBE2D2 mRNA; Gonadotropin-Releasing Hormone results in increased expression of UBE2D2 protein |
CTD |
PMID:16055746 |
|
NCBI chr18:27,638,399...27,680,386
Ensembl chr18:27,364,303...27,406,181
|
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
affects abundance |
ISO |
[ACE2 protein affects the abundance of Angiotensin I] which affects the abundance of Angiotensin II; ACE2 protein affects the abundance of Angiotensin II |
CTD |
PMID:27649628 |
|
NCBI chr X:33,925,458...33,972,851
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
ISO |
[[Lisinopril co-treated with chymostatin] affects the metabolism of AGT protein] which results in decreased abundance of Angiotensin II; [Lisinopril affects the metabolism of AGT protein] which results in decreased abundance of Angiotensin II |
CTD |
PMID:27649628 |
|
NCBI chr19:69,426,540...69,447,017
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Agtr2 |
angiotensin II receptor, type 2 |
increases expression |
EXP |
Angiotensin II results in increased expression of AGTR2 mRNA; Angiotensin II results in increased expression of AGTR2 protein |
CTD |
PMID:12969123 |
|
NCBI chr X:116,914,320...116,918,504
Ensembl chr X:112,120,228...112,124,057
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO |
naoxintong inhibits the reaction [Angiotensin II results in increased expression of BAX mRNA] |
CTD |
PMID:38230784 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression multiple interactions |
ISO |
Angiotensin II results in increased expression of CCL2 mRNA naoxintong inhibits the reaction [Angiotensin II results in increased expression of CCL2 mRNA] |
CTD |
PMID:38230784 |
|
NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
increases expression multiple interactions |
ISO |
Angiotensin II results in increased expression of COL1A1 mRNA NFE2L2 protein affects the reaction [Angiotensin II results in increased expression of COL1A1 mRNA] |
CTD |
PMID:33746155 |
|
NCBI chr10:80,380,458...80,397,461
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
increases expression |
ISO |
Angiotensin II results in increased expression of COL3A1 mRNA |
CTD |
PMID:33746155 |
|
NCBI chr 9:54,866,646...54,902,578
Ensembl chr 9:47,374,593...47,410,547
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
decreases expression multiple interactions |
EXP |
Angiotensin II results in decreased expression of CPT1A mRNA celastrol methyl ester inhibits the reaction [Angiotensin II results in decreased expression of CPT1A mRNA]; PPARA protein promotes the reaction [celastrol methyl ester inhibits the reaction [Angiotensin II results in decreased expression of CPT1A mRNA]] |
CTD |
PMID:37269933 |
|
NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Ednrb |
endothelin receptor type B |
increases expression |
EXP |
Angiotensin II results in increased expression of EDNRB protein |
CTD |
PMID:15007106 |
|
NCBI chr15:87,055,490...87,086,765
Ensembl chr15:80,643,043...80,672,115
|
|
G |
Esrra |
estrogen related receptor, alpha |
multiple interactions decreases expression |
EXP |
celastrol methyl ester inhibits the reaction [Angiotensin II results in decreased expression of ESRRA protein]; PPARA protein promotes the reaction [celastrol methyl ester inhibits the reaction [Angiotensin II results in decreased expression of ESRRA protein]] |
CTD |
PMID:37269933 |
|
NCBI chr 1:213,533,309...213,543,432
Ensembl chr 1:204,104,101...204,114,268
|
|
G |
Fis1 |
fission, mitochondrial 1 |
increases expression multiple interactions |
ISO |
Angiotensin II results in increased expression of FIS1 protein naoxintong inhibits the reaction [Angiotensin II results in increased expression of FIS1 protein] |
CTD |
PMID:38230784 |
|
NCBI chr12:25,345,239...25,360,135
Ensembl chr12:19,708,558...19,723,377
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases expression |
ISO |
naoxintong inhibits the reaction [Angiotensin II results in increased expression of IL1B mRNA] |
CTD |
PMID:38230784 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
ISO |
Angiotensin II results in increased expression of IL6 protein naoxintong inhibits the reaction [Angiotensin II results in increased expression of IL6 protein] |
CTD |
PMID:38230784 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
multiple interactions decreases expression |
ISO |
naoxintong inhibits the reaction [Angiotensin II results in decreased expression of MCL1 protein] |
CTD |
PMID:38230784 |
|
NCBI chr 2:185,884,840...185,912,532
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Myh6 |
myosin heavy chain 6 |
decreases expression multiple interactions |
EXP |
Angiotensin II results in decreased expression of MYH6 mRNA celastrol methyl ester inhibits the reaction [Angiotensin II results in decreased expression of MYH6 mRNA alternative form] |
CTD |
PMID:37269933 |
|
NCBI chr15:32,388,102...32,413,663
Ensembl chr15:28,417,616...28,441,720
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
NFE2L2 protein affects the reaction [Angiotensin II results in increased expression of COL1A1 mRNA]; NFE2L2 protein affects the reaction [Angiotensin II results in increased expression of NOX4 protein] |
CTD |
PMID:33746155 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nox4 |
NADPH oxidase 4 |
increases expression multiple interactions |
ISO |
Angiotensin II results in increased expression of NOX4 protein naoxintong inhibits the reaction [Angiotensin II results in increased expression of NOX4 mRNA] NFE2L2 protein affects the reaction [Angiotensin II results in increased expression of NOX4 protein] |
CTD |
PMID:33746155 PMID:38230784 |
|
NCBI chr 1:150,313,736...150,491,480
Ensembl chr 1:140,901,097...141,077,406
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions increases expression |
EXP |
celastrol methyl ester inhibits the reaction [Angiotensin II results in increased expression of NPPA mRNA] |
CTD |
PMID:37269933 |
|
NCBI chr 5:163,712,184...163,713,493
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nppb |
natriuretic peptide B |
multiple interactions increases expression |
EXP |
celastrol methyl ester inhibits the reaction [Angiotensin II results in increased expression of NPPB mRNA] |
CTD |
PMID:37269933 |
|
NCBI chr 5:163,699,955...163,701,314
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
affects response to substance |
ISO |
NR1I2 protein affects the susceptibility to Angiotensin II |
CTD |
PMID:33746155 |
|
NCBI chr11:75,965,717...76,006,733
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Pdha1 |
pyruvate dehydrogenase E1 subunit alpha 1 |
decreases expression multiple interactions |
EXP |
Angiotensin II results in decreased expression of PDHA1 mRNA celastrol methyl ester inhibits the reaction [Angiotensin II results in decreased expression of PDHA1 mRNA]; PPARA protein promotes the reaction [celastrol methyl ester inhibits the reaction [Angiotensin II results in decreased expression of PDHA1 mRNA]] |
CTD |
PMID:37269933 |
|
NCBI chr X:38,509,158...38,522,986
Ensembl chr X:34,700,409...34,714,311
|
|
G |
Pfkm |
phosphofructokinase, muscle |
multiple interactions increases expression |
EXP |
celastrol methyl ester inhibits the reaction [Angiotensin II results in increased expression of PFKM mRNA]; PPARA protein promotes the reaction [celastrol methyl ester inhibits the reaction [Angiotensin II results in increased expression of PFKM mRNA]] |
CTD |
PMID:37269933 |
|
NCBI chr 7:131,100,684...131,138,250
Ensembl chr 7:129,221,653...129,259,192
|
|
G |
Postn |
periostin |
increases expression |
ISO |
Angiotensin II results in increased expression of POSTN mRNA; Angiotensin II results in increased expression of POSTN protein |
CTD |
PMID:33746155 |
|
NCBI chr 2:140,677,774...140,709,304
Ensembl chr 2:138,527,696...138,559,099
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
EXP |
PPARA protein promotes the reaction [celastrol methyl ester inhibits the reaction [Angiotensin II results in decreased expression of CPT1A mRNA]]; PPARA protein promotes the reaction [celastrol methyl ester inhibits the reaction [Angiotensin II results in decreased expression of ESRRA protein]]; PPARA protein promotes the reaction [celastrol methyl ester inhibits the reaction [Angiotensin II results in decreased expression of PDHA1 mRNA]]; PPARA protein promotes the reaction [celastrol methyl ester inhibits the reaction [Angiotensin II results in decreased expression of TFAM protein]]; PPARA protein promotes the reaction [celastrol methyl ester inhibits the reaction [Angiotensin II results in increased expression of PFKM mRNA]] |
CTD |
PMID:37269933 |
|
NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
decreases expression multiple interactions |
EXP |
Angiotensin II results in decreased expression of PPARGC1A protein celastrol methyl ester inhibits the reaction [Angiotensin II results in decreased expression of PPARGC1A protein] |
CTD |
PMID:37269933 |
|
NCBI chr14:63,073,505...63,729,215
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ppargc1b |
PPARG coactivator 1 beta |
multiple interactions decreases expression |
EXP |
celastrol methyl ester inhibits the reaction [Angiotensin II results in decreased expression of PPARGC1B protein] |
CTD |
PMID:37269933 |
|
NCBI chr18:57,029,264...57,131,466
Ensembl chr18:54,758,902...54,861,194
|
|
G |
Tfam |
transcription factor A, mitochondrial |
decreases expression multiple interactions |
EXP |
Angiotensin II results in decreased expression of TFAM protein celastrol methyl ester inhibits the reaction [Angiotensin II results in decreased expression of TFAM protein]; PPARA protein promotes the reaction [celastrol methyl ester inhibits the reaction [Angiotensin II results in decreased expression of TFAM protein]] |
CTD |
PMID:37269933 |
|
NCBI chr20:17,355,373...17,367,422
Ensembl chr20:17,356,197...17,368,292
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression |
ISO |
naoxintong inhibits the reaction [Angiotensin II results in increased expression of TNF mRNA] |
CTD |
PMID:38230784 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
increases expression |
ISO |
Angiotensin-(1-7) increases expression of NR1H3 mRNA and protein in macrophages |
RGD |
PMID:25225013 |
RGD:401827926 |
NCBI chr 3:97,614,616...97,632,053
Ensembl chr 3:77,158,808...77,168,722
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions increases phosphorylation increases activity |
ISO EXP |
[2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Insulin] results in decreased phosphorylation of AKT1 protein; [2-amino-3,4-dimethylimidazo(4,5-f)quinoline co-treated with Insulin] results in decreased phosphorylation of AKT1 protein; [2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline co-treated with Insulin] results in decreased phosphorylation of AKT1 protein Insulin increases phosphorylation of Akt1 protein in cerebellar neurons Insulin increases activity of Akt1 protein in adipocytes Insulin increases activity of AKT1 protein in kidney cells |
CTD RGD |
PMID:37005939 PMID:12088287 PMID:9112399 PMID:9202156 PMID:9065430 |
RGD:408345250, RGD:408345243, RGD:407987424, RGD:407420264 |
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Akt2 |
AKT serine/threonine kinase 2 |
multiple interactions |
ISO |
[2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Insulin] results in decreased phosphorylation of AKT2 protein; [2-amino-3,4-dimethylimidazo(4,5-f)quinoline co-treated with Insulin] results in decreased phosphorylation of AKT2 protein; [2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline co-treated with Insulin] results in decreased phosphorylation of AKT2 protein |
CTD |
PMID:37005939 |
|
NCBI chr 1:92,004,705...92,061,420
Ensembl chr 1:82,883,547...82,933,817
|
|
G |
Akt3 |
AKT serine/threonine kinase 3 |
multiple interactions |
ISO |
[2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Insulin] results in decreased phosphorylation of AKT3 protein; [2-amino-3,4-dimethylimidazo(4,5-f)quinoline co-treated with Insulin] results in decreased phosphorylation of AKT3 protein; [2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline co-treated with Insulin] results in decreased phosphorylation of AKT3 protein |
CTD |
PMID:37005939 |
|
NCBI chr13:91,475,839...91,758,060
Ensembl chr13:88,946,091...89,225,708
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
EXP |
Insulin promotes the reaction [Ozone inhibits the reaction [Streptozocin results in increased expression of CASP1 mRNA]] |
CTD |
PMID:26614261 |
|
NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
Insulin promotes the reaction [Ozone inhibits the reaction [Streptozocin results in increased expression of CASP3 mRNA]] |
CTD |
PMID:26614261 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP |
Insulin promotes the reaction [Ozone inhibits the reaction [Streptozocin results in increased expression of CASP9 mRNA]] |
CTD |
PMID:26614261 |
|
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions |
ISO |
[Dexamethasone co-treated with Insulin co-treated with Indomethacin co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA; cordycepin inhibits the reaction [[Dexamethasone co-treated with Insulin co-treated with Indomethacin co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA] |
CTD |
PMID:34575692 |
|
NCBI chr 1:96,896,584...96,899,256
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
multiple interactions |
ISO |
[Dexamethasone co-treated with Insulin co-treated with Indomethacin co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FABP4 mRNA; cordycepin inhibits the reaction [[Dexamethasone co-treated with Insulin co-treated with Indomethacin co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FABP4 mRNA] |
CTD |
PMID:34575692 |
|
NCBI chr 2:93,488,251...93,492,961
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
EXP |
Insulin promotes the reaction [Ozone inhibits the reaction [Streptozocin results in increased expression of HIF1A mRNA]] |
CTD |
PMID:26614261 |
|
NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Insr |
insulin receptor |
decreases expression |
EXP |
insulin decreases expression of hepatic mRNA in streptozocin treated rats |
RGD |
PMID:1280238 |
RGD:15036814 |
NCBI chr12:5,991,135...6,129,275
Ensembl chr12:1,197,100...1,330,883
|
|
G |
Kcnn4 |
potassium calcium-activated channel subfamily N member 4 |
increases expression multiple interactions |
EXP |
insulin increases expression of Kcnn4 mRNA and protein in vascular smooth muscle cells 2-(2-amino-3-methoxyphenyl)chromen-4-one inhibits the reaction [insulin increases expression of Kcnn4 mRNA and protein in vascular smooth muscle cells] |
RGD |
PMID:21463632 PMID:21463632 |
RGD:401794561, RGD:401794561 |
NCBI chr 1:89,084,306...89,102,279
Ensembl chr 1:79,959,322...79,974,340
|
|
G |
Lpl |
lipoprotein lipase |
multiple interactions |
ISO |
[Dexamethasone co-treated with Insulin co-treated with Indomethacin co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of LPL mRNA; cordycepin inhibits the reaction [[Dexamethasone co-treated with Insulin co-treated with Indomethacin co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of LPL mRNA] |
CTD |
PMID:34575692 |
|
NCBI chr16:25,596,205...25,621,928
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
[[Paraquat results in increased phosphorylation of MAPK8 protein] which results in decreased abundance of Insulin] which results in increased abundance of Glucose |
CTD |
PMID:36394833 |
|
NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mir210 |
microRNA 210 |
increases expression multiple interactions |
EXP |
Insulin increases expression of Mir210 miRNA in myocardial cell LY294002 inhibits the reaction [Insulin increases expression of Mir210 miRNA in myocardial cell] |
RGD |
PMID:25968948 PMID:25968948 |
RGD:11086706, RGD:11086706 |
NCBI chr 1:205,755,923...205,756,032
Ensembl chr 1:196,326,337...196,326,454
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
[Dexamethasone co-treated with Insulin co-treated with Indomethacin co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG mRNA; cordycepin inhibits the reaction [[Dexamethasone co-treated with Insulin co-treated with Indomethacin co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG mRNA] |
CTD |
PMID:34575692 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
increases expression multiple interactions |
EXP ISO |
insulin increases expression of Srebf1 mRNA in hepatoma cells cilostazol inhibits the reaction [insulin increases expression of Srebf1 mRNA in liver cancer cells] cilostazol inhibits the reaction [insulin increases expression of Srebf1 mRNA in primary hepatocytes] cilostazol inhibits the reaction [insulin increases expression of Srebf1 mRNA in hepatoma cells] |
RGD |
PMID:24458133 PMID:24458133 PMID:24458133 PMID:24458133 PMID:24458133 PMID:24458133 More...
|
RGD:401842379, RGD:401842379, RGD:401842379, RGD:401842379, RGD:401842379, RGD:401842379 |
NCBI chr10:45,507,152...45,529,164
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
Insulin promotes the reaction [Ozone inhibits the reaction [Streptozocin results in increased expression of TNF mRNA]] |
CTD |
PMID:26614261 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Tnf |
tumor necrosis factor |
increases secretion |
EXP |
Novorapid inhibits the reaction [Lipopolysaccharide increases secretion of Tnf protein in serum] |
RGD |
PMID:18078960 |
RGD:15023464 |
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases activity multiple interactions |
ISO |
Neurotensin results in increased activity of FOS protein [Neurotensin results in increased activity of FOS protein] which results in increased expression of CXCL8 protein |
CTD |
PMID:17000667 |
|
NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
increases activity multiple interactions |
ISO |
Neurotensin results in increased activity of FOSL1 protein [Neurotensin results in increased activity of FOSL1 protein] which results in increased expression of CXCL8 protein |
CTD |
PMID:17000667 |
|
NCBI chr 1:212,183,885...212,192,391
Ensembl chr 1:202,754,529...202,764,930
|
|
G |
Junb |
JunB proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases activity |
ISO |
[Neurotensin results in increased activity of JUNB protein] which results in increased expression of CXCL8 protein |
CTD |
PMID:17000667 |
|
NCBI chr19:40,081,126...40,082,910
Ensembl chr19:23,176,294...23,178,035
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
increases activity multiple interactions |
ISO |
Neurotensin results in increased activity of NFKB1 protein [Neurotensin results in increased activity of NFKB1 protein] which results in increased expression of CXCL8 mRNA |
CTD |
PMID:17000667 |
|
NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Ntsr1 |
neurotensin receptor 1 |
affects binding |
ISO |
Neurotensin binds to NTSR1 protein |
CTD |
PMID:19874804 |
|
NCBI chr 3:187,983,778...188,033,934
Ensembl chr 3:167,606,215...167,656,377
|
|
G |
Ntsr2 |
neurotensin receptor 2 |
affects binding |
ISO |
Neurotensin binds to NTSR2 protein |
CTD |
PMID:19874804 |
|
NCBI chr 6:39,424,297...39,431,015
Ensembl chr 6:39,424,324...39,431,014
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions increases activity |
ISO |
[Neurotensin results in increased activity of RELA protein] which results in increased expression of CXCL8 mRNA |
CTD |
PMID:17000667 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:202,924,945...202,935,484
|
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression |
EXP |
Oxytocin results in increased expression of BCL2 protein |
CTD |
PMID:23707249 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Egfr |
epidermal growth factor receptor |
increases expression |
EXP |
Oxytocin results in increased expression of EGFR protein modified form |
CTD |
PMID:23707249 |
|
NCBI chr14:95,378,626...95,551,358
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression multiple interactions |
EXP |
Oxytocin results in increased expression of FOS protein Oxytocin inhibits the reaction [Methamphetamine results in increased expression of FOS protein] |
CTD |
PMID:20731630 |
|
NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Gdf9 |
growth differentiation factor 9 |
increases expression |
EXP |
Oxytocin results in increased expression of GDF9 protein |
CTD |
PMID:23707249 |
|
NCBI chr10:38,090,021...38,100,801
Ensembl chr10:37,595,679...37,599,672
|
|
G |
Has2 |
hyaluronan synthase 2 |
increases expression |
EXP |
Oxytocin results in increased expression of HAS2 protein |
CTD |
PMID:23707249 |
|
NCBI chr 7:90,002,929...90,028,933
Ensembl chr 7:88,113,326...88,128,933
|
|
G |
Klf4 |
KLF transcription factor 4 |
multiple interactions increases expression |
ISO |
KLF4 protein promotes the reaction [Oxytocin inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of SELE protein]]; KLF4 protein promotes the reaction [Oxytocin inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of VCAM1 protein]]; MAP2K5 protein promotes the reaction [Oxytocin results in increased expression of KLF4 mRNA]; MAP2K5 protein promotes the reaction [Oxytocin results in increased expression of KLF4 protein]; MEF2A protein promotes the reaction [Oxytocin results in increased expression of KLF4 mRNA]; MEF2A protein promotes the reaction [Oxytocin results in increased expression of KLF4 protein]; Oxytocin inhibits the reaction [malondialdehyde-low density lipoprotein, human results in decreased expression of KLF4 protein] Oxytocin results in increased expression of KLF4 mRNA; Oxytocin results in increased expression of KLF4 protein |
CTD |
PMID:29104011 |
|
NCBI chr 5:75,074,107...75,079,182
Ensembl chr 5:70,278,972...70,283,602
|
|
G |
Map2k5 |
mitogen activated protein kinase kinase 5 |
multiple interactions |
ISO |
MAP2K5 protein promotes the reaction [Oxytocin results in increased expression of KLF4 mRNA]; MAP2K5 protein promotes the reaction [Oxytocin results in increased expression of KLF4 protein] |
CTD |
PMID:29104011 |
|
NCBI chr 8:72,520,616...72,748,395
Ensembl chr 8:63,625,221...63,851,983
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases expression |
EXP |
Oxytocin results in increased expression of MAPK1 protein modified form |
CTD |
PMID:23707249 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases expression |
EXP |
Oxytocin results in increased expression of MAPK3 protein modified form |
CTD |
PMID:23707249 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mef2a |
myocyte enhancer factor 2a |
multiple interactions |
ISO |
MEF2A protein promotes the reaction [Oxytocin results in increased expression of KLF4 mRNA]; MEF2A protein promotes the reaction [Oxytocin results in increased expression of KLF4 protein] |
CTD |
PMID:29104011 |
|
NCBI chr 1:130,258,083...130,392,819
Ensembl chr 1:120,850,080...120,981,948
|
|
G |
Mknk2 |
MAPK interacting serine/threonine kinase 2 |
multiple interactions |
EXP |
Oxytocin inhibits the reaction [Cisplatin results in increased expression of MKNK2 mRNA] |
CTD |
PMID:21993003 |
|
NCBI chr 7:9,690,385...9,701,527
Ensembl chr 7:9,039,728...9,050,827
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
decreases response to substance |
EXP |
MMP2 protein results in decreased susceptibility to Oxytocin |
CTD |
PMID:22496348 |
|
NCBI chr19:30,327,643...30,355,856
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases response to substance |
EXP |
MMP9 protein results in decreased susceptibility to Oxytocin |
CTD |
PMID:22496348 |
|
NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Noxo1 |
NADPH oxidase organizer 1 |
multiple interactions |
EXP |
Oxytocin inhibits the reaction [Cisplatin results in increased expression of NOXO1 mRNA] |
CTD |
PMID:21993003 |
|
NCBI chr10:14,226,473...14,230,541
Ensembl chr10:13,721,473...13,726,061
|
|
G |
Oxtr |
oxytocin receptor |
multiple interactions increases expression |
EXP ISO |
Oxytocin analog binds to and results in decreased activity of OXTR protein Oxytocin results in increased expression of OXTR protein guizhi-fuling inhibits the reaction [Oxytocin results in increased expression of OXTR protein] |
CTD |
PMID:9502799 PMID:27340106 |
|
NCBI chr 4:147,154,374...147,171,723
Ensembl chr 4:145,599,561...145,614,674
|
|
G |
Plcb1 |
phospholipase C beta 1 |
affects localization |
ISO |
Oxytocin affects the localization of PLCB1 protein |
CTD |
PMID:11579162 |
|
NCBI chr 3:142,512,765...143,224,042
Ensembl chr 3:122,060,031...122,772,869
|
|
G |
Plcb3 |
phospholipase C beta 3 |
affects localization |
ISO |
Oxytocin affects the localization of PLCB3 protein |
CTD |
PMID:11579162 |
|
NCBI chr 1:213,572,499...213,589,585
Ensembl chr 1:204,144,956...204,160,228
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression multiple interactions |
EXP ISO |
Oxytocin results in increased expression of PTGS2 protein guizhi-fuling inhibits the reaction [Oxytocin results in increased expression of PTGS2 protein] |
CTD |
PMID:23707249 PMID:27340106 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Sele |
selectin E |
multiple interactions |
ISO |
KLF4 protein promotes the reaction [Oxytocin inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of SELE protein]]; Oxytocin inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of SELE mRNA]; Oxytocin inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of SELE protein] |
CTD |
PMID:29104011 |
|
NCBI chr13:78,935,997...78,945,905
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Tnfaip6 |
TNF alpha induced protein 6 |
increases expression |
EXP |
Oxytocin results in increased expression of TNFAIP6 protein |
CTD |
PMID:23707249 |
|
NCBI chr 3:56,911,398...56,930,797
Ensembl chr 3:36,502,188...36,521,649
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
KLF4 protein promotes the reaction [Oxytocin inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of VCAM1 protein]]; Oxytocin inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of VCAM1 mRNA]; Oxytocin inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of VCAM1 protein] |
CTD |
PMID:29104011 |
|
NCBI chr 2:206,723,050...206,742,783
Ensembl chr 2:204,038,114...204,057,958
|
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions |
ISO |
pasireotide promotes the reaction [BMP2 protein results in increased expression of ID1 mRNA] |
CTD |
PMID:23137853 |
|
NCBI chr 3:141,264,648...141,275,416
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
multiple interactions |
ISO |
pasireotide promotes the reaction [BMP4 protein results in increased expression of ID1 mRNA] |
CTD |
PMID:23137853 |
|
NCBI chr15:22,098,191...22,113,145
Ensembl chr15:19,618,542...19,623,306
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
multiple interactions |
ISO |
pasireotide promotes the reaction [BMP6 protein results in increased expression of ID1 mRNA] |
CTD |
PMID:23137853 |
|
NCBI chr17:26,523,704...26,785,558
Ensembl chr17:26,318,569...26,470,365
|
|
G |
Bmp7 |
bone morphogenetic protein 7 |
multiple interactions |
ISO |
pasireotide promotes the reaction [BMP7 protein results in increased expression of ID1 mRNA] |
CTD |
PMID:23137853 |
|
NCBI chr 3:182,059,318...182,135,273
Ensembl chr 3:161,516,462...161,716,788
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
multiple interactions |
ISO EXP |
NOG protein inhibits the reaction [pasireotide inhibits the reaction [FSHB protein results in increased expression of CYP11A1 mRNA]] |
CTD |
PMID:23137853 |
|
NCBI chr 8:67,318,665...67,330,196
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
multiple interactions |
EXP |
pasireotide inhibits the reaction [FSHB protein results in increased expression of CYP19A1 mRNA] |
CTD |
PMID:23137853 |
|
NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions |
ISO EXP |
NOG protein inhibits the reaction [pasireotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]]; NOG protein inhibits the reaction [pasireotide inhibits the reaction [FSHB protein results in increased abundance of Progesterone]]; NOG protein inhibits the reaction [pasireotide inhibits the reaction [FSHB protein results in increased expression of CYP11A1 mRNA]]; NOG protein inhibits the reaction [pasireotide inhibits the reaction [FSHB protein results in increased expression of HSD3B2 mRNA]]; NOG protein inhibits the reaction [pasireotide inhibits the reaction [FSHB protein results in increased expression of STAR mRNA]] pasireotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; pasireotide inhibits the reaction [FSHB protein results in increased abundance of Estradiol]; pasireotide inhibits the reaction [FSHB protein results in increased abundance of Progesterone]; pasireotide inhibits the reaction [FSHB protein results in increased expression of CYP11A1 mRNA]; pasireotide inhibits the reaction [FSHB protein results in increased expression of CYP19A1 mRNA]; pasireotide inhibits the reaction [FSHB protein results in increased expression of HSD3B2 mRNA]; pasireotide inhibits the reaction [FSHB protein results in increased expression of STAR mRNA] |
CTD |
PMID:23137853 |
|
NCBI chr 3:114,003,262...114,007,072
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Hsd3b2 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 |
multiple interactions |
EXP |
pasireotide inhibits the reaction [FSHB protein results in increased expression of HSD3B2 mRNA] |
CTD |
PMID:23137853 |
|
NCBI chr 2:188,784,614...188,812,535
Ensembl chr 2:186,095,897...186,101,852
|
|
G |
Id1 |
inhibitor of DNA binding 1 |
multiple interactions |
ISO |
pasireotide promotes the reaction [BMP2 protein results in increased expression of ID1 mRNA]; pasireotide promotes the reaction [BMP4 protein results in increased expression of ID1 mRNA]; pasireotide promotes the reaction [BMP6 protein results in increased expression of ID1 mRNA]; pasireotide promotes the reaction [BMP7 protein results in increased expression of ID1 mRNA] |
CTD |
PMID:23137853 |
|
NCBI chr 3:161,671,525...161,672,691
Ensembl chr 3:141,211,267...141,212,419
|
|
G |
Nog |
noggin |
multiple interactions |
ISO |
NOG protein inhibits the reaction [pasireotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]]; NOG protein inhibits the reaction [pasireotide inhibits the reaction [FSHB protein results in increased abundance of Progesterone]]; NOG protein inhibits the reaction [pasireotide inhibits the reaction [FSHB protein results in increased expression of CYP11A1 mRNA]]; NOG protein inhibits the reaction [pasireotide inhibits the reaction [FSHB protein results in increased expression of HSD3B2 mRNA]]; NOG protein inhibits the reaction [pasireotide inhibits the reaction [FSHB protein results in increased expression of STAR mRNA]] |
CTD |
PMID:23137853 |
|
NCBI chr10:74,625,874...74,627,501
Ensembl chr10:74,128,712...74,130,339
|
|
G |
Smad6 |
SMAD family member 6 |
decreases expression |
EXP |
pasireotide results in decreased expression of SMAD6 mRNA |
CTD |
PMID:23137853 |
|
NCBI chr 8:73,345,457...73,414,985
Ensembl chr 8:64,450,114...64,519,763
|
|
G |
Smad7 |
SMAD family member 7 |
decreases expression |
EXP |
pasireotide results in decreased expression of SMAD7 mRNA |
CTD |
PMID:23137853 |
|
NCBI chr18:71,263,508...71,291,849
Ensembl chr18:68,988,429...69,016,765
|
|
G |
Sstr1 |
somatostatin receptor 1 |
affects binding |
ISO |
pasireotide binds to SSTR1 protein |
CTD |
PMID:16625840 |
|
NCBI chr 6:81,567,237...81,571,759
Ensembl chr 6:75,832,530...75,836,802
|
|
G |
Sstr2 |
somatostatin receptor 2 |
affects binding |
ISO |
pasireotide binds to SSTR2 protein |
CTD |
PMID:16625840 |
|
NCBI chr10:99,163,353...99,170,519
Ensembl chr10:98,664,216...98,674,351
|
|
G |
Sstr3 |
somatostatin receptor 3 |
affects binding |
ISO |
pasireotide binds to SSTR3 protein |
CTD |
PMID:16625840 |
|
NCBI chr 7:111,973,049...111,980,250
Ensembl chr 7:110,092,575...110,099,769
|
|
G |
Sstr4 |
somatostatin receptor 4 |
affects binding |
ISO |
pasireotide binds to SSTR4 protein |
CTD |
PMID:16625840 |
|
NCBI chr 3:156,307,992...156,309,855
Ensembl chr 3:135,854,826...135,856,689
|
|
G |
Sstr5 |
somatostatin receptor 5 |
affects binding |
ISO |
pasireotide binds to SSTR5 protein |
CTD |
PMID:16625840 |
|
NCBI chr10:15,010,209...15,017,469
Ensembl chr10:14,506,868...14,512,946
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions |
ISO EXP |
NOG protein inhibits the reaction [pasireotide inhibits the reaction [FSHB protein results in increased expression of STAR mRNA]] |
CTD |
PMID:23137853 |
|
NCBI chr16:72,969,824...72,974,447
Ensembl chr16:66,264,807...66,271,672
|
|
|
G |
Kcna5 |
potassium voltage-gated channel subfamily A member 5 |
multiple interactions |
EXP |
Somatostatin inhibits the reaction [Dexamethasone results in increased expression of KCNA5 mRNA] |
CTD |
PMID:15955845 |
|
NCBI chr 4:161,040,853...161,044,311
Ensembl chr 4:159,350,097...159,357,697
|
|
G |
Ptpn1 |
protein tyrosine phosphatase, non-receptor type 1 |
multiple interactions |
ISO |
Somatostatin inhibits the reaction [Glucose increases expression of Ptpn1 protein in photoreceptor cells] |
RGD |
PMID:28050125 |
RGD:401976377 |
NCBI chr 3:177,056,588...177,106,424
Ensembl chr 3:156,638,769...156,687,504
|
|
G |
Sstr1 |
somatostatin receptor 1 |
increases expression |
ISO |
Somatostatin results in increased expression of SSTR1 mRNA |
CTD |
PMID:18575731 |
|
NCBI chr 6:81,567,237...81,571,759
Ensembl chr 6:75,832,530...75,836,802
|
|
G |
Sstr2 |
somatostatin receptor 2 |
increases expression |
ISO |
Somatostatin results in increased expression of SSTR2 mRNA |
CTD |
PMID:18575731 |
|
NCBI chr10:99,163,353...99,170,519
Ensembl chr10:98,664,216...98,674,351
|
|
G |
Sstr3 |
somatostatin receptor 3 |
increases expression |
ISO |
Somatostatin results in increased expression of SSTR3 mRNA |
CTD |
PMID:18575731 |
|
NCBI chr 7:111,973,049...111,980,250
Ensembl chr 7:110,092,575...110,099,769
|
|
G |
Sstr4 |
somatostatin receptor 4 |
increases expression |
ISO |
Somatostatin results in increased expression of SSTR4 mRNA |
CTD |
PMID:18575731 |
|
NCBI chr 3:156,307,992...156,309,855
Ensembl chr 3:135,854,826...135,856,689
|
|
G |
Sstr5 |
somatostatin receptor 5 |
increases expression |
ISO |
Somatostatin results in increased expression of SSTR5 mRNA |
CTD |
PMID:18575731 |
|
NCBI chr10:15,010,209...15,017,469
Ensembl chr10:14,506,868...14,512,946
|
|
|
G |
Cftr |
CF transmembrane conductance regulator |
increases activity |
ISO |
Vasopressins results in increased activity of CFTR protein |
CTD |
PMID:15513933 |
|
NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Mylk |
myosin light chain kinase |
affects response to substance |
EXP |
MYLK protein affects the susceptibility to Vasopressins |
CTD |
PMID:15347643 |
|
NCBI chr11:79,288,243...79,535,450
Ensembl chr11:65,783,008...66,030,261
|
|
|
G |
Cftr |
CF transmembrane conductance regulator |
increases activity |
ISO |
Vasotocin results in increased activity of CFTR protein |
CTD |
PMID:15685210 |
|
NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:46,560,885...46,728,756
|
|